title: The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.
abstract: In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Travi
authors.forename: Steven A
authors.initials: SA
authors.lastname: Pergam
authors.forename: Hu
authors.initials: H
authors.lastname: Xie
authors.forename: Paul
authors.initials: P
authors.lastname: Carpenter
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Kiem
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Boeckh
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001549:Benzamides; D003587:Cytomegalovirus / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014775:Virus Activation / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate